Maze Therapeutics (NASDAQ:MAZE) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Maze Therapeutics (NASDAQ:MAZE) in a report released on Thursday,Benzinga reports. They currently have a $50.00 price target on the stock.

Other equities research analysts have also issued reports about the company. Guggenheim boosted their price objective on Maze Therapeutics from $19.00 to $34.00 and gave the stock a “buy” rating in a research note on Monday. BTIG Research upped their price target on Maze Therapeutics from $30.00 to $37.00 and gave the company a “buy” rating in a research report on Friday, September 12th. Wall Street Zen upgraded Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. Finally, Wedbush initiated coverage on Maze Therapeutics in a research report on Tuesday, July 8th. They issued an “outperform” rating and a $17.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company. According to MarketBeat.com, Maze Therapeutics presently has an average rating of “Buy” and an average target price of $32.67.

Maze Therapeutics Trading Down 0.1%

NASDAQ:MAZE opened at $23.48 on Thursday. Maze Therapeutics has a 12 month low of $6.71 and a 12 month high of $25.50. The stock has a 50 day moving average of $16.00 and a two-hundred day moving average of $12.59.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.02.

Insider Buying and Selling

In related news, Director Richard H. Scheller sold 20,744 shares of the stock in a transaction on Monday, September 15th. The stock was sold at an average price of $22.37, for a total value of $464,043.28. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Hedge Funds Weigh In On Maze Therapeutics

Several large investors have recently bought and sold shares of the business. Bank of America Corp DE increased its holdings in Maze Therapeutics by 33.6% in the second quarter. Bank of America Corp DE now owns 5,782 shares of the company’s stock valued at $71,000 after buying an additional 1,455 shares during the last quarter. CWM LLC purchased a new position in Maze Therapeutics in the second quarter valued at $28,000. New York State Common Retirement Fund purchased a new position in Maze Therapeutics in the first quarter valued at $25,000. Legal & General Group Plc increased its holdings in Maze Therapeutics by 387.0% in the second quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock valued at $52,000 after buying an additional 3,371 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in Maze Therapeutics by 452.5% in the second quarter. Tower Research Capital LLC TRC now owns 4,608 shares of the company’s stock valued at $57,000 after buying an additional 3,774 shares during the last quarter.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.